This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Endo International plc
Drug Names(s): acrivastine & pseudoephedrine HCL
Description: SEMPREX-D Capsules (acrivastine and pseudoephedrine hydrochloride) are a fixed combination product formulated for oral administration.
Deal Structure: SEMPREX-D Capsules was originally developed by UCB.
UCB and Actient
In July 2010, UCB announced that it licensed U.S. marketing rights to six pharmaceutical products to Actient Pharmaceuticals, with an option for Actient to purchase those products. These products include SEMPREX-D Capsules. Under the terms of the agreement, UCB will receive an upfront payment upon closing as well as future royalty payments. Other details of the transaction have not been disclosed.
Actient and Auxilium
Auxilium announced that it has completed the acquisition of Actient Holdings. Auxilium will pay Actient unit holders $585 million in upfront cash a warrant for 1.25 million shares of Auxilium common stock with an exercise price of $17.80 per share and up to $50 million of contingent consideration based upon the achievement of future revenue targets. To finance the acquisition, Auxilium is using cash on hand and the proceeds from a new secured loan of $225 million from...See full deal structure in Biomedtracker
Partners: UCB SA
Semprex-D Capsules News
Pink Sheet Chart: FDA Recalls -- June 2, 2010
Pink Sheet June Drug Product Recalls
Pink Sheet Burroughs Wellcome's Semprex-D
Additional information available to subscribers only: